Navigation Links
Calcium Channel Blocker Adalat GITS Offer Additional Benefits

ACTION-trial shows medical and economic advantages of nifedipine GITS therapy


LEVERKUSEN, Germany, March 28, 2007 – Two recently published articles in the Journal of Clinical Epidemiology provide further evidence that the use of the long-acting calcium channel blocker (CCB) nifedipine GITS (Adalat? GITS) has additional benefits beyond its blood pressure lowing effect. A first publication from Lubsen et al. (Journal of Clinical Epidemiology 2007; first published online) demonstrates that while the blood pressure lowering effect of nifedipine GITS did play a major role in the reduction of debilitating stroke and new overt heart failure, the anti-anginal and vascular protective effects of nifedipine GITS seem to be just as important in reducing cardiovascular events. A second publication by Poole-Wilson et al. (Journal of Clinical Epidemiology 2007; first published online) also demonstrates that a nifedipine GITS therapy in patients with stable angina can help contain healthcare expenses by reducing the need for additional medication and the use of expensive diagnostic and surgical procedures. Both these papers are based on analyses of the ACTION-database. ACTION (A Coronary Disease Trial Investigating Outcome with Nifedipine GITS) collected data from 7,665 patients with stable angina pectoris.

Lowering blood pressure helps reduce stroke and heart failure
The ACTION-trial showed that adding nifedipine GITS to a best practice angina pectoris therapy significantly reduced the incidence of any stroke or TIA (28%) and the development of new overt heart failure (29%). Using an innovative statistical approach, Lubsen et al. found that nifedipine GITS’ ability to lower systolic blood pressure was largely responsible for these impressive results. The reduction in the risks of coronary angiography and surgery, attributed to nifedipine GITS on the other hand, are likely to be d
'"/>




Page: 1 2 3

Related medicine technology :

1. Calcium Plaque Build-up in the Arteries Leads to Coronary Heart Disease in Multi-Ethnic Groups
2. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
3. Analyzers Offer Point-of-Care Lipid Panels
4. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
5. Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
6. MUSC Research Offers Hope for Those Resistant to Depression Treatment
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Calcium Channel Blocker Adalat GITS Offer Additional Benefits
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ) ... focused on researching, developing, manufacturing and marketing biopharmaceutical products, ... quarter and first half ended June 30, 2011. ... Total net revenues increased by 29.0% over the ...
... 2011 Vycor Medical, Inc. ("Vycor" or the "Company") ... fiscal quarter ended March 31, 2011, the year ended ... 2010, June 30, 2010 and September 30, 2010 and ... Company,s periodic reports filed with the Securities and Exchange ...
Cached Medicine Technology:3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 23SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 33SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 43SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 63SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 73SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 83SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 93SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 103SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 113SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 123SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 133SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 143SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 153SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 163SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 173SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 183SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 19Vycor Medical, Inc. Restatement of Financial Statements 2Vycor Medical, Inc. Restatement of Financial Statements 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... techniques such as Dynamic Neuromuscular Stabilization, Extracorporeal Shock ... analysis. After moving to upgraded facilities in 2011, ... clinic. Now, owner Dr. Lev Kalika has launched ... injury prevention lab in the country. , The ...
(Date:11/28/2014)... The holiday season is fast approaching. As ... new collection of fashionable party dresses. What’s more, the company ... these brand new outfits; the special offer is valid until ... online supplier and it has received a lot of requests ... specially designed to flatter various body shapes; they are available ...
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Orlando, FL (PRWEB) November 28, 2014 ... management solutions, announced its Release v5.1 which provides ... and enhanced workflow options. , “As we ... we continue to provide more functionality and improved ... states Robert Gambotz, CEO for Novatus. “With the ...
(Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... treatment to her practice called Ultrashape that is designed to ... inches in just six weeks. Ultrashape has been praised by ... in results when compared to other types of external fat ... it,” said Dr. Walder. , According to Dr. Walder, ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... Madhya Pradesh government has decided to implement a new ... through several 'anganwadis' (mother and child care centres). ... years are in full swing in the 59,324 anganwadis. ... an official of the women and child welfare department. ...
... better for children suffering from asthma compared to ... effectiveness and safety of different medicines. ... children control asthma, clinical trials directly comparing them ... Medical. ,For the first time, researchers ...
... review in the current issue of the Cochrane Library journal ... (ED) - Cialis, Levitra and Viagra appear to be safe ... in a family of medications called phosphodiesterase type 5 (PDE-5) ... of ED. Experts have estimated that the diabetic men ...
... talk of HIV/AIDS falling on deaf ears? ‘Careless’ is perhaps too ... to be completely in-charge of their lives, yet throw caution to ... survey has shown that, nearly three out of four women, do ... ,The Body Shop and MTV got together for a ...
... Schering-Plough fungus-fighter drug - Noxafil, //which gained FDA approval ... with crippled immune systems, according to two studies financed ... were published in the New England Journal of Medicine. ... known generically as posaconazole, also seems to have fewer ...
... all set to tighten the screws on smoking and ... hearing starting on Jan 23, is scheduled in which ... before the committee. ,Under the original act ... sports and other popular events by tobacco companies is ...
Cached Medicine News:Health News:ED Drugs - Safe and Effective for Diabetic Men 2
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... exists as unbound or free testosterone. The ... with high affinity [1], while the remainder ... albumin-bound and free fractions may be biologically ... Measurement of the free or unbound fraction ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
Medicine Products: